{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:28:40Z","timestamp":1768793320656,"version":"3.49.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.dld.2021.05.033","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:18:43Z","timestamp":1624447123000},"page":"1381-1393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A reasoned approach to the treatment of autoimmune hepatitis"],"prefix":"10.1016","volume":"53","author":[{"given":"Diego","family":"Vergani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Terziroli Beretta-Piccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrgastro.2011.69","article-title":"Autoimmune hepatitis","volume":"8","author":"Mieli-Vergani","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.dld.2021.05.033_bib0002","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis\u2013Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12016-010-8236-9","article-title":"Cutting edge issues in autoimmune hepatitis","volume":"42","author":"Vergani","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0004","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bpg.2011.09.009","article-title":"Pathogenesis of autoimmune hepatitis","volume":"25","author":"Liberal","year":"2011","journal-title":"Best Practice Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2021.05.033_bib0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1600-065X.2001.1820104.x","article-title":"Control of T-cell activation by CD4+ CD25+ suppressor T cells","volume":"182","author":"Shevach","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1016\/j.dld.2021.05.033_bib0006","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0008","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.23792","article-title":"A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis","volume":"52","author":"Ferri","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","article-title":"Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis","volume":"25","author":"Longhi","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.dld.2021.05.033_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102619","article-title":"Regulatory T cells in autoimmune hepatitis: an updated overview","author":"Longhi","year":"2021","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","volume":"57","author":"Peiseler","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0012","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181107","article-title":"Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy","volume":"12","author":"Diestelhorst","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0014","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology"},{"issue":"33","key":"10.1016\/j.dld.2021.05.033_bib0015","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0017","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"European association for the study of the liver. EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.dld.2021.05.033_bib0018","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","article-title":"Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis","volume":"42","author":"Luth","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0019","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.dld.2020.04.012","article-title":"Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis","volume":"52","author":"Gerussi","year":"2020","journal-title":"Digest Liver Dis"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0021","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0022","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.05.033_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(20)30328-9","article-title":"Established and novel therapeutic options for autoimmune hepatitis","author":"Liberal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0024","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/apt.16035","article-title":"Review article: experimental therapies in autoimmune hepatitis","volume":"52","author":"Halliday","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0025","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the european reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0026","first-page":"2068","article-title":"Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. clinical gastroenterology and hepatology: the official clinical practice journal of the","volume":"17","author":"Pape","year":"2019","journal-title":"Am Gastroenterol Ass"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0027","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1210\/en.2012-2045","article-title":"New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation","volume":"154","author":"Vandevyver","year":"2013","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.dld.2021.05.033_bib0028","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0031","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-13708","article-title":"Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience","volume":"39","author":"Kanzler","year":"2001","journal-title":"Z Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0032","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","article-title":"Safety issues in the management of autoimmune hepatitis","volume":"7","author":"Czaja","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0033","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.05.033_bib0034","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1155\/1990\/708916","article-title":"Overview of newer glucocorticoid preparations for inflammatory bowel disease","volume":"4","author":"Brattsand","year":"1990","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","article-title":"The use of budesonide in the treatment of autoimmune hepatitis in Canada","volume":"22","author":"Zandieh","year":"2008","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0036","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0037","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0038","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jpeds.2013.06.064","article-title":"Budesonide for juvenile autoimmune hepatitis? Not yet","volume":"163","author":"Mieli-Vergani","year":"2013","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0039","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","article-title":"Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis","volume":"16","author":"Peiseler","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0040","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.05.033_bib0041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1529-8019.2002.01539.x","article-title":"Inhibitors of purine and pyrimidine synthesis: mycophenolate, azathioprine, and leflunomide","volume":"15","author":"Mimouni","year":"2002","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0042","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/liv.14513","article-title":"High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation","volume":"40","author":"Pape","year":"2020","journal-title":"Liver Internat"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0043","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","article-title":"Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis","volume":"45","author":"Heneghan","year":"2006","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0044","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.mpg.0000232331.93052.dd","article-title":"Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis","volume":"43","author":"Banerjee","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0046","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/MEG.0b013e32832ad5f7","article-title":"Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children","volume":"21","author":"Dumortier","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.dld.2021.05.033_bib0047","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0048","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/j.1572-0241.2006.00538.x","article-title":"Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites","volume":"101","author":"de Boer","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0049","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/bdra.20399","article-title":"Pregnancy outcome of women exposed to azathioprine during pregnancy","volume":"79","author":"Goldstein","year":"2007","journal-title":"Birth Defects Res Part A"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/gut.48.1.97","article-title":"Management and outcome of pregnancy in autoimmune hepatitis","volume":"48","author":"Heneghan","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0051","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00404-010-1540-z","article-title":"Pregnancy outcome in women with autoimmune hepatitis","volume":"284","author":"Aggarwal","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0052","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCG.0b013e318176b8c5","article-title":"Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes","volume":"43","author":"Terrabuio","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0053","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.12223","article-title":"Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis","volume":"37","author":"de Boer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0054","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/apt.12285","article-title":"Letter: allopurinol co-therapy is safe and effective in autoimmune hepatitis","volume":"37","author":"Al-Shamma","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0055","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2036.2008.03925.x","article-title":"Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease","volume":"29","author":"Hindorf","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0056","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/apt.12511","article-title":"A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis","volume":"38","author":"Kennedy","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0058","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","article-title":"The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine","volume":"110","author":"Pratt","year":"1996","journal-title":"Gastroenterology"},{"issue":"40","key":"10.1016\/j.dld.2021.05.033_bib0059","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v22.i40.9012","article-title":"Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review","volume":"22","author":"Meijer","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00042737-200504000-00012","article-title":"Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine","volume":"17","author":"de Boer","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0061","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cgh.2017.07.032","article-title":"Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis","volume":"16","author":"Legue","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0062","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/apt.14939","article-title":"Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands","volume":"48","author":"van den Brand","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0063","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Internat"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0064","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy","volume":"18","author":"Devlin","year":"2004","journal-title":"Can J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease","volume":"39","author":"Czaja","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0066","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0067","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0068","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0069","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cgh.2007.02.030","article-title":"Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy","volume":"5","author":"Inductivo-Yu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2014.05.003","article-title":"Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study","volume":"4","author":"Jothimani","year":"2014","journal-title":"J Clin Exper Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0071","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0072","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","article-title":"Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine","volume":"51","author":"Giannakopoulos","year":"2019","journal-title":"Digest Liver Dis"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0073","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0074","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0075","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0076","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0077","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0078","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","article-title":"Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis","volume":"94","author":"Fernandes","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0079","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0080","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.05.033_bib0081","article-title":"Long-term Observation of Cyclosporine as Second-line Therapy in Adults of Severe Acute Autoimmune Hepatitis","author":"Noguchi","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.dld.2021.05.033_bib0082","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/00365521.2020.1821764","article-title":"Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis","volume":"55","author":"Roberts","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0083","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gut.36.3.459","article-title":"Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis","volume":"36","author":"Jackson","year":"1995","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0084","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5694\/j.1326-5377.1985.tb123140.x","article-title":"Cyclosporin, a new treatment for autoimmune chronic active hepatitis","volume":"143","author":"Mistilis","year":"1985","journal-title":"Med J Aust"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004836-199312000-00012","article-title":"A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis","volume":"17","author":"Person","year":"1993","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0086","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0087","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","article-title":"Follow-up of children with autoimmune hepatitis treated with cyclosporine","volume":"43","author":"Cuarterolo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0088","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000002776","article-title":"Autoimmune hepatitis in children: prednisone plus azathioprine versus cyclosporine: a randomized trial","volume":"71","author":"Cuarterolo","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0089","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.dld.2018.10.018","article-title":"Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine","volume":"51","author":"Nastasio","year":"2019","journal-title":"Digest Liver Dis"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365521.2016.1236398","article-title":"The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience","volume":"52","author":"Al Taii","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0091","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"issue":"23","key":"10.1016\/j.dld.2021.05.033_bib0092","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0093","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","article-title":"Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience","volume":"34","author":"Tannous","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0094","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0095","first-page":"771","article-title":"Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0096","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1651-2227.2012.02745.x","article-title":"Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis","volume":"101","author":"Marlaka","year":"2012","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0097","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.13907","article-title":"Expert clinical management of autoimmune hepatitis in the real world","volume":"45","author":"Liberal","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl.1","key":"10.1016\/j.dld.2021.05.033_bib0098","first-page":"A61","article-title":"Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction","volume":"44","author":"Heneghan","year":"1999","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0099","first-page":"15","article-title":"mTOR Inhibitors at a Glance","volume":"7","author":"Zheng","year":"2015","journal-title":"Mol Cell Pharm"},{"issue":"11","key":"10.1016\/j.dld.2021.05.033_bib0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0101","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/MPG.0b013e318291feaa","article-title":"Sirolimus as rescue therapy in pediatric autoimmune hepatitis","volume":"58","author":"Kurowski","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0102","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s10620-015-4022-0","article-title":"Refractory Autoimmune Hepatitis: Beyond Standard Therapy","volume":"61","author":"Rubin","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.dld.2021.05.033_bib0103","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use","volume":"50","author":"Ytting","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0104","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Reports"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0106","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","article-title":"A case of autoimmune hepatitis treated with rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Reports Gastroenterol"},{"issue":"11","key":"10.1016\/j.dld.2021.05.033_bib0107","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","article-title":"Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome","volume":"139","author":"Carey","year":"2011","journal-title":"Rev Med Chil"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MCG.0b013e3180f60b7a","article-title":"Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis","volume":"42","author":"Evans","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0109","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","article-title":"Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature","volume":"26","author":"Santos","year":"2006","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0110","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0111","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/2050640618768922","article-title":"Real-world management of juvenile autoimmune liver disease","volume":"6","author":"de Boer","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.dld.2021.05.033_bib0112","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0113","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0114","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF levels in patients with autoimmune hepatitis","volume":"68","author":"Migita","year":"2007","journal-title":"Hum Immunol"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0116","doi-asserted-by":"crossref","first-page":"e3194","DOI":"10.1097\/MD.0000000000003194","article-title":"B-cell activating factor belonging to the tumour necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepatitis","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0117","first-page":"23","article-title":"Circulating levels of interleukin-6, interleukin-8, and tumour necrosis factor-alpha in children with autoimmune hepatitis","volume":"20","author":"Maggiore","year":"1995","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0118","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.510300412","article-title":"Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis","volume":"30","author":"Cookson","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0119","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","article-title":"Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis","volume":"117","author":"Czaja","year":"1999","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.meg.0000108344.41221.8b","article-title":"Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease\u2013a possible target for infliximab treatment","volume":"16","author":"Agnholt","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0121","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0122","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2169\/internalmedicine.51.6824","article-title":"Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab","volume":"51","author":"Fujii","year":"2012","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0123","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as rescue therapy in paediatric autoimmune hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.dld.2021.05.033_bib0124","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/ajg.2009.433","article-title":"A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade","volume":"104","author":"Weiler-Normann","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2021.05.033_bib0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11586210-000000000-00000","article-title":"Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab","volume":"24","author":"Cravo","year":"2010","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MPG.0000000000001137","article-title":"Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease","volume":"63","author":"Mostamand","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0127","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","article-title":"Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis","volume":"187","author":"Ozorio","year":"2007","journal-title":"Med J Aust"},{"issue":"24","key":"10.1016\/j.dld.2021.05.033_bib0128","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumour necrosis factor alpha therapy: A single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0129","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1007\/s10620-014-3323-z","article-title":"Infliximab leading to autoimmune hepatitis: an increasingly recognized side effect","volume":"59","author":"Yilmaz","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1055\/s-0030-1255353","article-title":"Toll-like receptor 4 and hepatic fibrogenesis","volume":"30","author":"Pradere","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.05.033_bib0132","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fphys.2012.00138","article-title":"Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms","volume":"3","author":"Yang","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.dld.2021.05.033_bib0133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2017.07.012","article-title":"JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis","volume":"812","author":"Hsu","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0134","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.intimp.2014.07.008","article-title":"Role of alpha-lipoic acid in LPS\/d-GalN induced fulminant hepatic failure in mice: studies on oxidative stress, inflammation and apoptosis","volume":"22","author":"Xia","year":"2014","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0136","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/bph.13394","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","author":"Wang","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0137","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/08916934.2019.1641200","article-title":"Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis","volume":"52","author":"Czaja","year":"2019","journal-title":"Autoimmunity"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0138","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0198-8859(01)00344-5","article-title":"CTLA-4\/CD 28 region polymorphisms in children from families with autoimmune hepatitis","volume":"62","author":"Djilali-Saiah","year":"2001","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/cei.12956","article-title":"Immunosuppressive drugs affect interferon (IFN)-gamma and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis","volume":"189","author":"Grant","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.dld.2021.05.033_bib0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2016.05.005","article-title":"CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease","volume":"72","author":"Liberal","year":"2016","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0141","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/hep.29307","article-title":"Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis\/autoimmune sclerosing cholangitis","volume":"66","author":"Liberal","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0142","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hep.24039","article-title":"Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis","volume":"53","author":"Longhi","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0143","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0144","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","article-title":"Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis","volume":"142","author":"Longhi","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","article-title":"Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis","volume":"47","author":"Longhi","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0146","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.22914","article-title":"Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells","volume":"50","author":"Longhi","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0147","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"issue":"6029","key":"10.1016\/j.dld.2021.05.033_bib0148","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.dld.2021.05.033_bib0149","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.dld.2021.05.033_bib0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0151","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0152","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.dld.2021.05.033_bib0153","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2015.1037282","article-title":"The therapeutic potential of regulatory T cells for the treatment of autoimmune disease","volume":"19","author":"Bluestone","year":"2015","journal-title":"Expert Opin Ther Targets"},{"issue":"315","key":"10.1016\/j.dld.2021.05.033_bib0154","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0155","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0156","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0157","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.21658","article-title":"Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2","volume":"46","author":"Longhi","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0158","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.gastro.2005.12.020","article-title":"Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2","volume":"130","author":"Ma","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.05.033_bib0159","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fimmu.2014.00046","article-title":"Regulatory T cells as immunotherapy","volume":"5","author":"Singer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2021.05.033_bib0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-017-0002-5","article-title":"Targeting IL-2: an unexpected effect in treating immunological diseases","volume":"3","author":"Ye","year":"2018","journal-title":"Signal Transduct Targeted Therapy"},{"issue":"22","key":"10.1016\/j.dld.2021.05.033_bib0161","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.dld.2021.05.033_bib0162","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0163","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0164","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.dld.2021.05.033_bib0165","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.dld.2021.05.033_bib0166","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.dld.2021.05.033_bib0167","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.12940","article-title":"Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases","volume":"188","author":"Jeffery","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0168","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dld.2021.05.033_bib0169","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2021.05.033_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102591","article-title":"Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis","volume":"117","author":"Buitrago-Molina","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.dld.2021.05.033_bib0171","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells","volume":"56","author":"Bell","year":"2015","journal-title":"J Autoimmun"},{"issue":"215","key":"10.1016\/j.dld.2021.05.033_bib0172","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci Transl Med"},{"issue":"40","key":"10.1016\/j.dld.2021.05.033_bib0173","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1073\/pnas.1112722108","article-title":"Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells","volume":"108","author":"Beavis","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.dld.2021.05.033_bib0174","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.dld.2021.05.033_bib0175","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1172\/JCI33185","article-title":"Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice","volume":"118","author":"Tsang","year":"2008","journal-title":"J Clin Invest"},{"issue":"45","key":"10.1016\/j.dld.2021.05.033_bib0176","doi-asserted-by":"crossref","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis","volume":"106","author":"Wright","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.dld.2021.05.033_bib0177","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammat"},{"issue":"5","key":"10.1016\/j.dld.2021.05.033_bib0178","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"issue":"6295","key":"10.1016\/j.dld.2021.05.033_bib0179","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.dld.2021.05.033_bib0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bbmt.2012.12.011","article-title":"Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model)","volume":"19","author":"Azar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.dld.2021.05.033_bib0181","doi-asserted-by":"crossref","first-page":"21834","DOI":"10.18632\/oncotarget.15662","article-title":"PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple sclerosis M.smegmatis model","volume":"8","author":"Migliara","year":"2017","journal-title":"Oncotarget"},{"issue":"1-2","key":"10.1016\/j.dld.2021.05.033_bib0182","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jns.2011.07.050","article-title":"Preimplantation factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model","volume":"312","author":"Weiss","year":"2012","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.dld.2021.05.033_bib0183","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12020-011-9438-5","article-title":"Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice","volume":"40","author":"Weiss","year":"2011","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.dld.2021.05.033_bib0184","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep4.1239","article-title":"Randomized, double-blind, placebo-controlled, single ascending dose trial of synthetic preimplantation factor in autoimmune hepatitis","volume":"2","author":"O'Brien","year":"2018","journal-title":"Hepatol Commun"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:18:11Z","timestamp":1761625091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821003078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":184,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1590865821003078"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.05.033","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A reasoned approach to the treatment of autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}